FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136994764> ?p ?o ?g. }

• W3136994764 endingPage "154749" @default.
• W3136994764 startingPage "154749" @default.
• W3136994764 abstract "Background Polycystic ovary syndrome (PCOS) is the most common metabolic and endocrine disorder among reproductive-age women, and the leading cause of anovulatory infertility. 11β-hydroxysteroid dehydrogenases-1 (11β-HSD1) catalysing the conversion of inactive cortisone to active cortisol plays a crucial role in various metabolic diseases. However, whether 11β-HSD1 is associated with the pathogenesis of PCOS and whether 11β-HSD1 can be a treating target of PCOS remain unknown. Methods This study was first designed to explore the role of 11β-HSD1 in PCOS development and the effect of selective 11β-HSD1 inhibitor administration on PCOS treatment. Follicular fluid and granulosa cells (GCs) were collected from 32 non-PCOS patients and 37 patients with PCOS to measure cortisol and 11β-HSDs levels. Female Sprague-Dawley rats (3-week-old) were injected with dehydroepiandrosterone (DHEA) to induce PCOS and their ovaries were collected to measure the abundance of corticosterone (CORT) and 11β-HSDs. To determine the role of 11β-HSD1 in PCOS development, we overexpressed 11β-HSD1 in the ovaries of female rats (5-week-old) or knocked down the expression of 11β-HSD1 in the ovaries from PCOS rats via lentivirus injection. After lentivirus infection, the body weights, ovarian weights, estrous cycles, reproductive hormones and morphology of the ovary were analysed in rats from different experimental groups. Then to figure out the translational potential of the selective 11β-HSD1 inhibitor in treating PCOS, PCOS rats were treated with BVT.2733, a selective 11β-HSD1 inhibitor and a cluster of PCOS-like traits were analysed, including insulin sensitivity, ovulatory function and fertility of rats from the Control, PCOS and PCOS+BVT groups. Rat ovarian explants and human GCs were used to explore the effect of CORT or cortisol on ovarian extracellular matrix remodelling. Results The elevated expression of 11β-HSD1 contributed to the increased cortisol and corticosterone (CORT) concentrations observed in the ovaries of PCOS patients and PCOS rats respectively. Our results showed that ovarian overexpression of 11β-HSD1 induced a cluster of PCOS phenotypes in rats including irregular estrous cycles, reproductive hormone dysfunction and polycystic ovaries. While knockdown of ovarian 11β-HSD1 of PCOS rats reversed these PCOS-like changes. Additionally, the selective 11β-HSD1 inhibitor BVT.2733 alleviated PCOS symptoms such as insulin resistance (IR), irregular estrous cycles, reproductive hormone dysfunction, polycystic ovaries, ovulatory dysfunction and subfertility. Moreover, we showed that cortisol target ovarian insulin signalling pathway and ovarian extracellular matrix (ECM) remodelling in vivo, in ovarian explants and in GCs. Conclusion Elevated 11β-HSD1 abundance in ovarian is involved in the pathogenesis of PCOS by impairing insulin signalling pathway and ECM remodelling. Selective inhibition of 11β-HSD1 ameliorates a cluster of PCOS phenotypes. Our study demonstrates the selective 11β-HSD1 inhibitor as a novel and promising strategy for the treatment of PCOS." @default.
• W3136994764 created "2021-03-29" @default.
• W3136994764 creator A5016147078 @default.
• W3136994764 creator A5018228131 @default.
• W3136994764 creator A5028603894 @default.
• W3136994764 creator A5029887231 @default.
• W3136994764 creator A5039002118 @default.
• W3136994764 creator A5052453000 @default.
• W3136994764 creator A5054741849 @default.
• W3136994764 creator A5055207211 @default.
• W3136994764 creator A5060429184 @default.
• W3136994764 creator A5068297054 @default.
• W3136994764 creator A5068379691 @default.
• W3136994764 creator A5071445293 @default.
• W3136994764 creator A5074427178 @default.
• W3136994764 creator A5078856013 @default.
• W3136994764 creator A5083723295 @default.
• W3136994764 date "2021-06-01" @default.
• W3136994764 modified "2023-10-17" @default.
• W3136994764 title "Addressing the role of 11β-hydroxysteroid dehydrogenase type 1 in the development of polycystic ovary syndrome and the putative therapeutic effects of its selective inhibition in a preclinical model" @default.
• W3136994764 cites W1965576057 @default.
• W3136994764 cites W1967263394 @default.
• W3136994764 cites W1970460637 @default.
• W3136994764 cites W1975045088 @default.
• W3136994764 cites W1996319758 @default.
• W3136994764 cites W2000464446 @default.
• W3136994764 cites W2001623636 @default.
• W3136994764 cites W2015052247 @default.
• W3136994764 cites W2016125985 @default.
• W3136994764 cites W2022227132 @default.
• W3136994764 cites W2030444886 @default.
• W3136994764 cites W2041655797 @default.
• W3136994764 cites W2058294720 @default.
• W3136994764 cites W2075331912 @default.
• W3136994764 cites W2084304926 @default.
• W3136994764 cites W2111912017 @default.
• W3136994764 cites W2113329249 @default.
• W3136994764 cites W2120558931 @default.
• W3136994764 cites W2128654723 @default.
• W3136994764 cites W2131465407 @default.
• W3136994764 cites W2156597872 @default.
• W3136994764 cites W2157391392 @default.
• W3136994764 cites W2160472557 @default.
• W3136994764 cites W2168489955 @default.
• W3136994764 cites W2171638975 @default.
• W3136994764 cites W2172288279 @default.
• W3136994764 cites W2275092747 @default.
• W3136994764 cites W2289753669 @default.
• W3136994764 cites W2321704487 @default.
• W3136994764 cites W2481420451 @default.
• W3136994764 cites W2508503562 @default.
• W3136994764 cites W2515732365 @default.
• W3136994764 cites W2592452345 @default.
• W3136994764 cites W2778670551 @default.
• W3136994764 cites W2893710206 @default.
• W3136994764 cites W2895464557 @default.
• W3136994764 cites W2903464283 @default.
• W3136994764 cites W2914874015 @default.
• W3136994764 cites W2930685593 @default.
• W3136994764 cites W3016603280 @default.
• W3136994764 cites W3018038959 @default.
• W3136994764 cites W3093766904 @default.
• W3136994764 cites W4211231448 @default.
• W3136994764 doi "https://doi.org/10.1016/j.metabol.2021.154749" @default.
• W3136994764 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33722534" @default.
• W3136994764 hasPublicationYear "2021" @default.
• W3136994764 type Work @default.
• W3136994764 sameAs 3136994764 @default.
• W3136994764 citedByCount "8" @default.
• W3136994764 countsByYear W31369947642022 @default.
• W3136994764 countsByYear W31369947642023 @default.
• W3136994764 crossrefType "journal-article" @default.
• W3136994764 hasAuthorship W3136994764A5016147078 @default.
• W3136994764 hasAuthorship W3136994764A5018228131 @default.
• W3136994764 hasAuthorship W3136994764A5028603894 @default.
• W3136994764 hasAuthorship W3136994764A5029887231 @default.
• W3136994764 hasAuthorship W3136994764A5039002118 @default.
• W3136994764 hasAuthorship W3136994764A5052453000 @default.
• W3136994764 hasAuthorship W3136994764A5054741849 @default.
• W3136994764 hasAuthorship W3136994764A5055207211 @default.
• W3136994764 hasAuthorship W3136994764A5060429184 @default.
• W3136994764 hasAuthorship W3136994764A5068297054 @default.
• W3136994764 hasAuthorship W3136994764A5068379691 @default.
• W3136994764 hasAuthorship W3136994764A5071445293 @default.
• W3136994764 hasAuthorship W3136994764A5074427178 @default.
• W3136994764 hasAuthorship W3136994764A5078856013 @default.
• W3136994764 hasAuthorship W3136994764A5083723295 @default.
• W3136994764 hasConcept C126322002 @default.
• W3136994764 hasConcept C134018914 @default.
• W3136994764 hasConcept C187785154 @default.
• W3136994764 hasConcept C2776992908 @default.
• W3136994764 hasConcept C2777391703 @default.
• W3136994764 hasConcept C2777688143 @default.
• W3136994764 hasConcept C2777911890 @default.
• W3136994764 hasConcept C2778324911 @default.
• W3136994764 hasConcept C2779234561 @default.
• W3136994764 hasConcept C2779279991 @default.
• W3136994764 hasConcept C2779306644 @default.

• next